Locations
United States · Milwaukee, WI, USA · South Milwaukee, WI, USA
industry
Pharmaceuticals
Size
1 - 10 employees
Stage
Other
founded in
2007
Seeking to redefine what is possible®. Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat Central Nervous System (CNS) disorders. Promentis’ drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The company’s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
Something looks off?